Уважаемые коллеги, доброго времени суток! Представляем вам польское научное издание Journal of Contemporary Brachytherapy. Журнал имеет третий квартиль, издаётся в Termedia Publishing House Ltd., находится в открытом доступе, его SJR за 2021 г. равен 0,485, импакт-фактор 1,788, печатный ISSN - 1689-832X, электронный - 2081-2841, предметные области - Онкология, Радиология и радиационная медицина. Вот так выглядит обложка:
Редактором является Адам Чичел, контактные данные - adam.chichel@wco.pl, brachyterapia@wco.pl, wojciechburchardt@hotmail.com.
Это международный и междисциплинарный журнал, в котором будут публиковаться статьи с оригинальными исследованиями, а также обзоры статей. Основные темы журнала включают: клиническую брахитерапию, комбинированное лечение, достижения в области радиобиологии, гипертермии и биологии опухолей, а также физические аспекты, имеющие отношение к брахитерапии, особенно в области визуализации, дозиметрии и планирования лучевой терапии. Оригинальные материалы будут включать экспериментальные исследования комбинированных методов лечения, сенсибилизации опухоли и защиты нормальных тканей, молекулярную радиационную биологию и клинические исследования лечения рака с помощью брахитерапии. Еще одной областью интересов является образовательная часть журнала.
Адрес издания - https://www.termedia.pl/Journal/Journal_of_Contemporary_Brachytherapy-54
Пример статьи, название - Long-term clinical outcomes of non-melanoma skin cancer patients treated with electronic brachytherapy. Заголовок (Abstract)
Purpose: High-dose-rate electronic brachytherapy (eBx) is a non-surgical treatment option for non-melanoma skin cancer (NMSC) patients. This study assessed long-term effectiveness and safety of eBx for the treatment of NMSC.
Material and methods: A chart review was conducted to identify subjects who had five or more years since their last eBx treatment fraction. Subjects meeting these criteria were contacted to determine their interest in participating in a long-term follow-up study. Those who agreed, underwent a follow-up visit where consent was obtained, and their lesions were clinically assessed for recurrence and long-term skin toxicities. History and demographic data were retrospectively collected, and treatment method was verified.
Results: 183 subjects with 185 lesions were enrolled into this study at four dermatology centers in two practices in California. Three subjects in the analysis were less than 5 years from the last treatment to follow-up visit. All lesions were stage 1 basal cell carcinoma, squamous cell carcinoma, or squamous cell carcinoma in situ. Recurrence rate for the 183 subjects was 1.1%. Long-term skin toxicities were reported in 70.0% of the subjects. Hypopigmentation grade 1 was observed in 65.9% of the lesions, telangiectasia grade 1 was seen in 22.2%, scarring grade 1 in two subjects (1.1%), hyperpigmentation grade 1 in two subjects (1.1%), and induration grade 2 in one patient (0.5%). The induration grade 2 was located on the upper back and did not limit instrumental activities of daily living (ADLs).
Conclusions: Electronic brachytherapy for the treatment of non-melanoma skin cancer is safe and effective, showing excellent long-term 98.9% local control through a median follow-up of 7.6 years (n = 183), with minimal long-term toxicities.
Key words: electronic brachytherapy, non-melanoma skin cancer, squamous cell carcinoma, local control, basal cell carcinoma.